152 results about "Monoamine neurotransmitter" patented technology

Aryl alkanol piperazine derivatives of the formula

and pharmaceutical compositions comprising the same. Also disclosed are methods for treating depression using the pharmaceutical compositon. Compounds of the invention have excellent dual inhibitory actions to the uptake of the mono-amines neurotransmitter, good antidepressant activities and minor side effects.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, attention deficit hyperactivity disorder, fibromyalgia, irritable bowel syndrome, and/or premature ejaculation are described.

The present invention relates to (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse.

The invention discloses a preparation method of a CdTe@SiO2 quantum dot surface monoamine neurotransmitter molecularly imprinted polymer. The preparation method comprises the following steps of: synthesizing CdTe@SiO2 quantum dots in a water phase, carrying out rotary evaporation till water is completely volatized, and washing off unreacted substances by absolute ethyl alcohol; adding the obtained CdTe@SiO2 quantum dots to a pore-foaming agent, sequentially adding template molecules, functional monomers and a crosslinking agent after uniform ultrasonic dispersion, and stirring and reacting for 20 hours under the protection of N2; centrifuging a reaction liquid, discarding a supernatant, and washing obtained solids to remove the template molecules to obtain the CdTe@SiO2 quantum dot surface monoamine neurotransmitter molecularly imprinted polymer. The material synthesized by the method has the advantages that a quantum dot fluorescent probe is high in sensitivity and simple and convenient to detect and has the characteristics that the molecularly imprinted polymer is high in selectivity and affinity and can be directly used for determining monoamine neurotransmitters in biological fluids.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

The invention relates to application of tetrahydrocurcumin in preparing an antidepressant and a method for preparing a solid dispersion of the tetrahydrocurcumin. The invention aims to provide the application of the tetrahydrocurcumin to prepare the antidepressant. The tetrahydrocurcumin and a surfactant are mixed in certain proportion to obtain the solid dispersion of the tetrahydrocurcumin. The method for preparing the solid dispersion of the tetrahydrocurcumin comprises the following steps that: according to the weight ratio of 1:3-1:30, the tetrahydrocurcumin and the surfactant are heated until completely melted, frozen in a low-temperature environment, and taken out, dried and crushed to obtain the solid dispersion of the tetrahydrocurcumin. The tetrahydrocurcumin and the solid dispersion of the tetrahydrocurcumin are used for preparing drugs, health care products, foods or food additives of relieving mental depression. The tetrahydrocurcumin has the function of relieving mental depression, and the function of the tetrahydrocurcumin is possibly related with the influence on a monoamine neurotransmitter system; moreover, compared with fluoxetine, the tetrahydrocurcumin has the advantages of low toxicity and good curing effect.

The invention belongs to the field of analytical chemistry and particularly relates to a detecting method for determining various neurotransmitters on the basis of in situ derivation. The method is characterized in that 4'-carbonyl chloride-rhodamine is used as the derivative reagent for the first time, the ultrasonic assistance-in situ derivation-dispersive liquid-liquid microextraction technology is used to derive amino acid and monoamine neurotransmitters, and the ultra-high performance liquid chromatography triple quadrupoles tandem mass spectrum with multiple reaction monitoring modes is used to perform qualitative and quantitative detection; three internal standard substances (isoprenaline, 5-ketoindole-2-carboxylic acid and norleucine) are used for building the linear equations of the neurotransmitters of three chemical structures; the existence of the neurotransmitters is accurately determined by quantification through an internal standard method. The detecting method is simple, fast, high in sensitivity, good in selectivity, good in recovery rate, capable of fast and accurately determining the neurotransmitters, and the like.

Relating to the medicine field, the invention discloses the use of acetagastrodine in preparing medicines to prevent and treat vascular dementia and Alzheimer disease. The invention also provides a medicinal composition for preventing and treating senile dementia and its capsule as well as sustained release agent. Animal tests show that: acetagastrodine can substantially enhance the learning and memory abilities of rats with vascular dementia, reduce the activity of AchE in brains, enhance the vitality of ChAT in brains, and remarkably reduce Glu content; acetagastrodine has significant protective effect on damaged PC12 cells caused by H2O2 by enhancing the vitality of SOD and total ATP enzyme in PC12 cells and reducing the content of MDA and LD; acetagastrodine can substantially enhance the learning and memorizing abilities of AD model rats, enhance the CAT content in brains of the model rats, reduce the MAO vitality and simultaneously prevent the decrease of neurotransmitters. Acetagastrodine is better than gastrodin in terms of the treatment effects on VD and AD, and enjoys good clinical application prospect.

Accordingly, the invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and at least one NMDA receptor antagonists or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof.

The present invention relates to methods of inhibiting native and promiscuous uptake of biogenic amine neurotransmitters with triple reuptake inhibitors in the treatment of conditions affected by monoamine neurotransmitters.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described.

The invention relates to a pharmaceutical composition for preventing and treating Parkinson's disease. The pharmaceutical composition consists of active ingredients and medically acceptable auxiliary materials, and is characterized in that the active ingredients consist of the following components in percentage by weight: rhizoma acori graminei volatile oil extracted from rhizoma acori graminei accounting for 25-45 percent and tortoise plastron water extract extracted from tortoise plastron accounting for55-75 percent. By adopting the pharmaceutical composition, neurological integrals of Parkinson's model rats can be obviously improved, the content of monoamine neurotransmitters in rat brains is increased, reduction of tyrosine hydroxylase in brain is inhibited, and the effect of preventing and treating the Parkinson's disease is obvious.

The invention relates to a pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and at least one acetylcholinesterase inhibitor or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

The invention discloses a detection method for determining monoamine neurotransmitters based on derivatization. According to the detection method, the monoamine neurotransmitters and derivative reagent n-butanal and the like generate derivative reaction, and an obtained derivatization product is analyzed and detected by an ultrahigh-phase liquid chromatogram-mass spectrum combined system; the monoamine neurotransmitters include dopamine, noradrenaline and 5-hydroxytryptamine. Derivatization reaction conditions of the method have the advantages of simpleness, gentleness, quickness and environmental friendliness; the method can process samples in batch and has the advantages of high analyzing speed, low analyzing method quantitative lower limit and good linear range, precise and accuracy; simultaneous quantitative analysis on the dopamine, the noradrenaline and the 5-hydroxytryptamine in trace rat brain microdialysate is achieved.

The invention belongs to the field of traditional Chinese medicine, and particularly relates to a preparing method of a lily bulb and rhizoma rehmanniae soup standard decoction with an anti-depressionfunction. Firstly, records about dosages of a classical prescription lily bulb and rhizoma rehmanniae soup, production places of geo-authentic crude drugs and preparing methods of the classical prescription are looked up in the literature of past dynasties, and then the classical prescription lily bulb and rhizoma rehmanniae soup standard decoction is prepared; after the lily bulb and rhizoma rehmanniae soup is intervened in, the content of monoamine neurotransmitters 5-HT, NE and DA is increased, the content of inhibitory neurotransmitters is lowered, and the content of excitatory neurotransmitters is increased; finally, a high performance liquid chromatograph is utilized for analyzing the active ingredients for the drug effect of the decoction, a modern scientific basis is provided forthe depression treatment function mechanism and drug-using formula of the classical prescription lily bulb and rhizoma rehmanniae soup, and the decoction has high theoretical significance and clinicalvalue.

The invention provides a novel application of swertisin and a derivative thereof in preparing an antidepressant drug. The swertisin has an obvious antidepressant effect, can significantly improve functions of a monoamine neurotransmitter system, has an auxiliary therapeutic effect for depression and symptoms thereof, and provides a novel selection for treating depression clinically.

The invention relates to a composite which is composed of (2Z, 8Z, 10E)-2,8,10-pentadecane triene-4,6-diyne-1-alcohol and (2Z, 8E, 10E)-2,8,10-pentadecane triene-4,6-diyne-1-alcohol according to the proportion of 1:(1-4) or is composed of (2Z, 8Z, 10E)-2,8,10-heptadecane triene-4,6-diyne-1-alcohol and (2Z, 8E, 10E)-2,8,10-heptadecane triene-4,6-diyne-1-alcohol according to the proportion of 1:(1-4). The composite disclosed by the invention is obtained by being extracted and separated from traditional Chinese medicine radix bupleuri. The result of an in-vitro monoamine neurotransmitter reuptake inhibition experiment shows that the composite disclosed by the invention has triple inhibition effects on the reuptake of 5-HT (5-Hydroxytryptamine), NA (noradrenalin) and DA (Dopamine), is higher than the effective part of ease powder petroleum ether and the part of radix bupleuri petroleum ether in inhibition ratio and is higher than positive control drugs, namely fluoxetine, norpramin and 6-hydroxydopamine, in inhibiting effect. According to the invention, two composites can be applied to prepare a drug used for preventing and curing depression.

The invention discloses novel application of forsythin belonging to active components of natural medicinal plants, and particularly relates to application of forsythin as the only active ingredient to preparation of a medicine for improving a cognitive function and treating Alzheimer's diseases. Animal and cell research results indicate that the forsythin has the exact function of improving the cognitive function and can remarkably improve the spatial learning and memory ability of animals in an aging and Alzheimer's disease model, the level of a center monoamine neurotransmitter of an old-aged animal is increased, the genetic expression of presenilin 2 in a rat brain of an Alzheimer's disease model is reduced, and the survival rate of neuroblastoma cells induced by beta-amyloid protein is increased. The forsythin is matched with relevant auxiliary materials, a health care product or a medicine for purposefully improving the cognitive function and treating the Alzheimer's diseases can be prepared by a conventional preparation method, and the health care product and the medicine can be used for delaying and improving relevant diseases of cognitive hypofunction such as the course of the Alzheimer's diseases, enhancing the healthy quality and the life quality of old people and realizing a healthy aging social value.